ENDRA Life Sciences Inc
NASDAQ:NDRA
ENDRA Life Sciences Inc
NASDAQ:NDRA
Price:
3.52
USD
2.92%
Market Closed
Market Cap:
$4.1m
Balance Sheet
Balance Sheet Decomposition
ENDRA Life Sciences Inc
ENDRA Life Sciences Inc
Balance Sheet Decomposition is not available for
ENDRA Life Sciences Inc
ENDRA Life Sciences Inc
Balance Sheet
ENDRA Life Sciences Inc
ENDRA Life Sciences Inc
Currency: USD
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & Cash Equivalents |
0
|
0
|
0
|
6
|
6
|
6
|
7
|
9
|
5
|
3
|
3
|
|
| Cash |
0
|
0
|
0
|
6
|
6
|
6
|
7
|
9
|
5
|
3
|
3
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
3
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
|
| Total Current Assets |
0
|
0
|
0
|
6
|
7
|
7
|
8
|
12
|
8
|
3
|
3
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
0
|
1
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
0
|
1
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
3
|
0
|
|
| Total Assets |
1
N/A
|
0
-30%
|
0
N/A
|
6
+1 149%
|
7
+18%
|
7
-1%
|
9
+22%
|
13
+47%
|
9
-28%
|
7
-27%
|
4
-34%
|
|
| Liabilities | ||||||||||||
| Accounts Payable |
0
|
0
|
0
|
1
|
1
|
1
|
0
|
1
|
1
|
0
|
0
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
0
|
|
| Short-Term Debt |
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
0
|
0
|
1
|
1
|
1
|
2
|
1
|
2
|
2
|
1
|
1
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
1
|
|
| Total Liabilities |
0
N/A
|
0
+140%
|
1
+475%
|
1
-38%
|
1
+14%
|
2
+149%
|
2
-34%
|
2
+31%
|
2
-1%
|
1
-47%
|
2
+73%
|
|
| Equity | ||||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
7
|
10
|
13
|
18
|
28
|
45
|
57
|
69
|
82
|
92
|
103
|
|
| Additional Paid In Capital |
8
|
10
|
12
|
23
|
34
|
50
|
64
|
79
|
89
|
98
|
106
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
1
N/A
|
0
-59%
|
1
N/A
|
5
N/A
|
6
+18%
|
5
-24%
|
7
+51%
|
11
+50%
|
7
-33%
|
6
-21%
|
3
-55%
|
|
| Total Liabilities & Equity |
1
N/A
|
0
-30%
|
0
N/A
|
6
+1 149%
|
7
+18%
|
7
-1%
|
9
+22%
|
13
+47%
|
9
-28%
|
7
-27%
|
4
-34%
|
|
| Shares Outstanding | ||||||||||||
| Common Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
3
|
0
|
1
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Switch to:
Switch to:
See Also
Discover More
